131 related articles for article (PubMed ID: 7932546)
1. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.
Thaisrivongs S; Tomich PK; Watenpaugh KD; Chong KT; Howe WJ; Yang CP; Strohbach JW; Turner SR; McGrath JP; Bohanon MJ
J Med Chem; 1994 Sep; 37(20):3200-4. PubMed ID: 7932546
[No Abstract] [Full Text] [Related]
2. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
4. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
[TBL] [Abstract][Full Text] [Related]
5. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
[TBL] [Abstract][Full Text] [Related]
6. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.
Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D
J Med Chem; 1994 Aug; 37(17):2664-77. PubMed ID: 8064795
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of HIV protease: unique non-peptide active site templates.
Tait BD; Domagala J; Ellsworth EL; Ferguson D; Gajda C; Hupe D; Lunney EA; Tummino PJ
J Mol Recognit; 1996; 9(2):139-42. PubMed ID: 8877805
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
[TBL] [Abstract][Full Text] [Related]
10. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA
Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973
[TBL] [Abstract][Full Text] [Related]
11. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
12. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
[No Abstract] [Full Text] [Related]
16. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors.
Kirkiacharian S; Thuy DT; Sicsic S; Bakhchinian R; Kurkjian R; Tonnaire T
Farmaco; 2002 Sep; 57(9):703-8. PubMed ID: 12385519
[TBL] [Abstract][Full Text] [Related]
18. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
[TBL] [Abstract][Full Text] [Related]
19. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.
Vacca JP
Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186
[No Abstract] [Full Text] [Related]
20. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
